SecBot SecBot
8-K ·Filed Jun 16, 2026

ELUT

ELUTIA INC.
NEUTRAL
Impact 3/10
Horizonmonths Processed5mo ago SEC0001104659-26-074660
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

The 3M share increase provides headroom for future equity compensation but does not represent immediate dilution. Monitor future 10-Q filings for actual share issuance under the plan. No near-term catalyst from this filing.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.9914
T+0 close · Jun 16, 2026 · via day close
Latest settled
−18.30%
T+60 · $0.8100
Vs SPY
−21.45%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 17 $0.9914entry
  2. T+1 · 5mo ago +6.92%α +6.14% · $1.06
  3. T+5 · 5mo ago −1.04%α +0.00% · $0.9811
  4. T+20 · 4mo ago −4.18%α −5.49% · $0.9500
  5. T+60 · 2mo ago −18.30%α −21.45% · $0.8100
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Elutia Inc. filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders, where shareholders approved an amendment to the 2020 Incentive Award Plan, increasing authorized shares by 3,000,000. All director nominees were elected, and advisory say-on-pay was approved with an annual frequency recommendation. This is a routine governance filing with no material financial impact.

Key Facts

  • Shareholders approved the First Amendment to the 2020 Incentive Award Plan, increasing authorized shares by 3,000,000 shares of Class A common stock.
  • Annual meeting had 34,041,545 shares present (77.0% of outstanding) as of April 17, 2026 record date.
  • David Colpman and Kevin Rakin were elected as Class III directors.
  • PricewaterhouseCoopers LLP ratified as independent auditor for FY2026.
  • Advisory say-on-pay approved with 25,617,864 votes for; annual frequency recommended.

Financial Impact

Potential dilution from up to 3,000,000 additional shares authorized for equity awards; no immediate financial impact.

dilution

Risk Factors

  • Potential dilution from future equity awards under the expanded plan.
  • No material change to business fundamentals or financial outlook.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-074660
Document: 0001104659-26-074660-index-headers.html0001104659-26-074660
Document: 0001104659-26-074660-index.html0001104659-26-074660
Document: 0001104659-26-074660.txt0001104659-26-074660

Track record

7 reports on ELUT

Performance horizon
Filters
  1. Nov 5, 202611d ago Press Release Neutral 4/10 No price data
  2. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $0.8374 Now $0.8230 −1.72% settles Dec 7
  3. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $0.8615 Now $0.8230 −4.47% settles Nov 20
  4. Jul 31, 202615w ago Press Release Neutral 1/10 Entry $0.8568 to $0.8800 Now $0.8230 −3.94% ▲ +2.71% −0.28% vs SPY
  5. Jun 16, 202621w ago 8-K Neutral 3/10 Viewing Entry $0.9914 to $0.9500 Now $0.8230 −16.99% ▼ −4.18% −5.49% vs SPY
  6. May 14, 202626w ago 8-K Neutral 5/10 Entry $1.03 to $0.9690 Now $0.8230 −20.10% ▼ −5.92% −8.04% vs SPY
  7. Mar 11, 202635w ago 8-K Mixed 7/10 Entry $1.15 to $1.13 Now $0.8230 −28.43% ▼ −1.74% −3.71% vs SPY
Showing 7 of 7

US Market Status

Market Closed · Opens in 6h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 16, 2026